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Objective: End-stage coagulation and the structure/function of fibrin are implicated in the pathogenesis of ischemic
stroke. We explored whether genetic variants associated with end-stage coagulation in healthy volunteers account
for the genetic predisposition to ischemic stroke and examined their influence on stroke subtype.
Methods: Common genetic variants identified through genome-wide association studies of coagulation factors and
fibrin structure/function in healthy twins (n 5 2,100, Stage 1) were examined in ischemic stroke (n 5 4,200 cases)
using 2 independent samples of European ancestry (Stage 2). A third clinical collection having stroke subtyping (total
8,900 cases, 55,000 controls) was used for replication (Stage 3).
Results: Stage 1 identified 524 single nucleotide polymorphisms (SNPs) from 23 linkage disequilibrium blocks having
significant association (p < 5 3 1028) with 1 or more coagulation/fibrin phenotypes. The most striking associations
included SNP rs5985 with factor XIII activity (p 5 2.6 3 102186), rs10665 with FVII (p 5 2.4 3 10247), and rs505922
in the ABO gene with both von Willebrand factor (p 5 4.7 3 10257) and factor VIII (p 5 1.2 3 10236). In Stage 2,
the 23 independent SNPs were examined in stroke cases/noncases using MOnica Risk, Genetics, Archiving and
Monograph (MORGAM) and Wellcome Trust Case Control Consortium 2 collections. SNP rs505922 was nominally
associated with ischemic stroke (odds ratio 5 0.94, 95% confidence interval 5 0.88–0.99, p 5 0.023). Independent
replication in Meta-Stroke confirmed the rs505922 association with stroke, beta (standard error, SE) 5 0.066 (0.02),
p 5 0.001, a finding specific to large-vessel and cardioembolic stroke (p 5 0.001 and p 5 < 0.001, respectively) but
not seen with small-vessel stroke (p 5 0.811).
Interpretation: ABO gene variants are associated with large-vessel and cardioembolic stroke but not small-vessel dis-
ease. This work sheds light on the different pathogenic mechanisms underpinning stroke subtype.
ANN NEUROL 2012;73:16–31
Ischemic stroke is among the leading causes of deathand disability in high-income countries.1 EuroCLOT is
a European Union–funded multicenter study established
to identify the genetic variants contributing to end-stage
coagulation, as a means of exploring whether the same
variants contribute to risk of ischemic stroke. It is known
that genetic factors account for approximately 60% of
the risk of thrombosis,2 and studies have demonstrated
the influence of genetic factors on the individual compo-
nents of coagulation and fibrinolysis. Furthermore, ex
vivo measures of fibrin structure and fibrinolysis have
been shown to be heritable.3 The nature of the structure
and function of fibrin has been shown to influence clot
behavior, and earlier work by the EuroCLOT consortium
has demonstrated heritability of fibrin clot phenotypes
measured by a high-throughput turbidimetric assay and
several regions of linkage.4 The goal of this study was to
extend these observations by using the genome-wide
association (GWA) approach to identify common genetic
loci associated with coagulation phenotypes and to deter-
mine whether associated loci were further associated with
the clinically important phenotype ischemic stroke and
its different subtypes. GWA studies have identified com-
mon genetic loci of small effect associated with clinical
phenotypes such as coronary artery disease.5 The GWA
method allows an agnostic study of variation within the
genome, unbiased by prior knowledge of the cellular
pathways involved or the use of candidate genes, and has
been successful in finding hundreds of gene loci to
date.6 The overall aim was to determine whether genetic
variants associated with coagulation and fibrin structure
function were risk factors for ischemic stroke and if so
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whether such associations differed between stroke
subtypes.
Subjects and Methods
We used a 3-stage study design to identify common variants
influencing coagulation and fibrin structure/function in the nor-
mal population and then tested genome-wide significant inde-
pendent single nucleotide polymorphisms (SNPs) for association
with stroke in subjects of Northern European extraction (Fig 1).
To study the broad range of hemostatic variables contributing to
end-stage coagulation, GWA studies of fibrin structure/function
ex vivo, fibrin turnover (D-dimer) in vivo, and individual hemo-
static components were performed in a healthy volunteer cohort
of twins (Stage 1). In Stage 2, those variants found to be inde-
pendently associated with coagulation or fibrin structure/function
were assessed as risk factors for ischemic stroke in cases and con-
trols. In Stage 3, the top 4 SNPs from the meta-analysis of ische-
mic stroke were examined for replication in a third clinical col-
lection of stroke having information on whether stroke resulted
from occlusion of large-vessel, small-vessel, or cardiac emboli.
Detailed methods are provided below. Written informed consent
was obtained from participants in the study, and each individual
study group obtained local ethics approval.
Phenotyping the Cohorts
TwinsUK. The subjects were obtained from the TwinsUK
(TUK) registry (www.twinsuk.ac.uk) at King’s College London,
United Kingdom, which has been ascertained by a national
media campaign.7 For historical reasons, the majority of twin
volunteers are female. TUK subjects have been shown to be
representative of the wider general populations for genetic and
lifestyle factors associated with a variety of traits.8 TUK subjects
were phenotyped for fibrin structure/function, D-dimer, and
hemostatic factors, according to methods described in detail
elsewhere.9–12 In brief, fibrin structure/function was assessed
using a turbidimetric assay, whereas D-dimer (as a measure of
in vivo fibrin turnover), coagulation factors (F) VII, VIII, FXII,
FXIII A and B subunits (FXIIIA, FXIIIIB), prothrombin, and
von Willebrand Factor (vWF) were quantified by enzyme-
linked immunosorbent assay, and fibrinogen, FVII, and FXIII
by functional activity assays.
The MOnica Risk, Genetics, Archiving and Monograph
(MORGAM) Cohort. The cohorts of the MORGAM project
consist of the respondents of representative adult population sam-
ples.13 This study includes cohorts from a variety of centers,
including Finland (FINRISK, ATBC), France (Lille, Strasbourg,
Toulouse), Italy (Brianza), Northern Sweden, and Northern Ire-
land (Belfast) as described at http://www.ktl.fi/publications/mor-
gam/cohorts. The participants were examined and DNA was col-
lected at baseline, and they were followed up for stroke and acute
coronary events. Genotyping was carried out in a case–cohort set-
ting.14 In MORGAM cohorts, the end-point used was the subject
presenting with first ischemic stroke. For some events the diagno-
sis was based on validation, and for some on the clinical or death
certificate diagnosis (International Classification of Diseases
[ICD]-9 codes 433 or 434, or ICD-10 code I63).
Wellcome Trust Case Control Consortium 2. The Well-
come Trust Case Control Consortium 2 (WTCCC2) ischemic
stroke study comprises ischemic stroke cases recruited from 3
centers in the United Kingdom (St George’s London, Oxford,
and Edinburgh) and 1 center in Munich, Germany. In all cases,
ischemic stroke was defined as a focal neurological deficit last-
ing >24 hours; in 1 cohort (St George’s), cases of transient is-
chemic attack with associated recent brain infraction were also
included. Cerebral infraction was confirmed on brain imaging
with computed tomography (CT) or magnetic resonance (MR)
imaging, which was performed in 100% of cases, and extensive phe-
notyping was performed to allow stroke subtyping using a modified
TOAST classification.15 Full details of populations and investigation
performed have been previously published.16 Imaging of the cere-
bral arteries using carotid and vertebral duplex ultrasound and/or
MR angiography or CT angiography was performed in >95%,
echocardiography in 59.7%. Controls for the UK cases were the
shared WTCCC2 controls drawn from the National Blood Service
or the 1958 Birth Cohort Study (http://www.b58cgene.sgul.ac.uk).
German controls were from the population-based KORAgen study
(http://www.helmholtz-muenchen.de/en/kora-en/kora-home-
page/index.html). This study group was used primarily in Stage
2 but also for subgroup analysis in Stage 3.
MetaStroke. MetaStroke is a project of the International
Stroke Genetics Consortium and comprises ischemic stroke cases
whose DNA has been collected and undergone GWA scan,
recruited from centers in Europe (BRAINS [Bio-Repository of
DNA in Stroke], United Kingdom; DeCODE, Iceland; Cerebro-
vascular Diseases Registry (CEDIR), Milan, Italy; Rotterdam, the
Netherlands), USA (Atherosclerosis Risk in Communities study;
Cardiovascular Health Study; Framingham Heart Study; Genetics
of Early Onset Stroke Study; Heart Protection Study; Heart and
Vascular Health; Ischemic Stroke Genetics Study; Massachusetts
General Hospital Genes Affecting Stroke Risk and Outcome
study), and Australia (Australian Stroke Genetics Collaborative).
Ischemic stroke was defined clinically as a focal neurological defi-
cit lasting >24 hours. In almost all case–control studies, a high
level of brain imaging and extensive phenotyping was performed,
although this was less detailed in some of the prospective studies.
In those studies with adequate investigations to allow stroke sub-
typing, this was performed using a modified TOAST classifica-
tion.15 Controls were collected by the individual groups.
Genotyping and Within-Cohort Analysis
TUK. Genotyping was performed in 3 different genotypic
batches using Human Hap 300 k Duo and Human Hap610
Quad array (Illumina, San Diego, CA). Genotyping results
from the different arrays were collated and quality control was
performed as described previously,17 including retention of
those SNPs with sufficiently high genotyping rates (95% or
above) and Hardy–Weinberg equilibrium (p > 0.0001). Impu-
tation of nongenotyped SNPs was performed to HapMap2
Caucasian population haplotypes using IMPUTE version 2.18
Population substructure and admixture was excluded in TUK
using Eigenvector analysis.
MORGAM. Four SNPS (rs10665, rs2022309, rs5985,
and rs651007) were genotyped at the National Institute for
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Health and Welfare in Finland. Several sample- and plate-spe-
cific quality control measures were implemented to minimize
errors, and in addition genotyping quality was assessed from
5% blind duplicate samples in each 96-well plate. For 234 sam-
ples with low DNA yield, DNA was amplified and genotyped
as previously described.19 Genotyping was performed using the
MassARRAY System and iPLEX Gold chemistry (Sequenom,
San Diego, CA) with standard protocol. Genotype clusters were
manually reviewed using Typer 4.0 software (Sequenom), and
genotype calls were corrected where necessary. Genotyping suc-
cess rate was >95% for all but 1 SNP (rs2022309, 91.3%),
with an average success rate of 95.7%. No discrepancies were
identified among a total of 1,256 successful blind duplicate ge-
notype pairs. Cox regression analysis adapted for the case–
cohort data was used to assess the association between the geno-
types and ischemic stroke in the MORGAM cohorts, assuming
an additive genotypic effect. The analysis was stratified by
cohort and sex.
WTCCC2. Stroke cases were genotyped using the Illu-
mina 660Q platform. Shared WTCCC2 controls were geno-
typed using the Illumina 1M Duo platform. German controls
were genotyped using the Illumina 550 platform. Analysis of
the UK and German cohorts was performed independently
using PLINK20 after quality control checking using a genotyp-
ing call rate of 98%, Hardy–Weinberg equilibrium call rate of
1e 220, and checks for individual relatedness and population
stratification. The UK and German cases were then meta-ana-
lyzed using METAL.21 Samples were identified and removed if
the genome-wide patterns of diversity differed from those of the
collection at large, interpreting them as likely to be due to biases
or artifacts. To do so, we used a Bayesian clustering approach to
infer outlying individuals on the basis of call rate, heterozygosity,
ancestry, and average probe intensity. We used a hidden Markov
model to infer identity by descent along the genome and
removed individuals iteratively to obtain a set with pair-wise
identity by descent <5%. Samples were also removed if their
inferred gender was discordant with the recorded gender or if
<90% of the SNPs typed by Sequenom (Sequenom iPLEX assay
for 4 gender SNPs) were concordant with the genome-wide data.
For the EuroCLOT study, individual UK and German cohort
and meta-analysis results were examined for the 23 available ge-
notypes. This was performed for the phenotype of all ischemic
stroke, together with the ischemic stroke subtypes of small-vessel
disease, large-vessel disease, and cardioembolic stroke.
MetaStroke. Genotyping of the 13 MetaStroke contribu-
tors was performed independently by each group, using either
Illumina or Affymetrix (Santa Clara, CA) platforms. Further
details on cases and controls, genotyping, and imputation are
available in Supplementary Table 3.
Statistical Analysis
Stage 1. We used multiple linear regression models to assess
association between genotypes and phenotypes, using age as a
covariate. The phenotypes examined in the TUK cohort were
inverse-normal transformed to satisfy the assumption of nor-
mality of trait distribution of the linear models. Association
FIGURE 1: Flow chart showing study design and cohorts involved. The 3 stages of the study design are shown, with number of
cases in each sample. GWA 5 genome-wide association; n 5 size of the cohort; SNP 5 single nucleotide polymorphism; TUK
5 TwinsUK; WTCCC2 5 Wellcome Trust Case Control Consortium 2.
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analysis was carried out using Merlin22 to control for family
structure within the dataset. Independence of the effects con-
ferred by SNPs in the same region was assessed by means of a
backward stepwise regression analysis on the trait with which
they were associated. This yielded 23 statistically independent
significant SNPs (p < 5 3 1028), associated with at least 1
quantitative outcome, which were taken forward for examina-
tion in the clinical groups at Stage 2. This stage of the analysis
was performed using Stata for Windows version 10 (Stata-
Corp, College Station, TX) with adjustment for the twins’
relatedness.
Stage 2. The 23 independent SNPs remaining significant
after multiple regression were carried through to investigation
of association with ischemic stroke in MORGAM and
WTCCC2. Results for each were meta-analyzed using a fixed
effects inverse variance weighting implemented in METAL.21
Stage 3. The 4 most significantly associated SNPs from
Stage 2 were tested for association with overall ischemic stroke
in Meta-Stroke. This international collaboration brings together
GWA studies in ischemic stroke and (depending on SNP)
includes 8,900 cases of ischemic stroke and 55,000 controls. In
addition, subgroup analysis was possible (in MetaStroke and
WTCCC2), as stroke events had been subphenotyped into
large-vessel, small-vessel, and cardioembolic stroke by many of
the contributing study groups, using the TOAST classifica-
tion.15 Within MetaStroke, samples were excluded from analysis
TABLE 1. Stage 1: Characteristics of the TwinsUK Discovery Sample
Trait No. Mean Min Max SD
Age, yr 2,128 50.4 17.3 80.1 12.72
BMI, kg/m2 2,124 25.5 15.2 52.4 4.7
Female gender, % 95.6 — — — —
D-dimer, ng/ml 1,362 104.9 9 3,740 151.3
FX antigen, U/ml 2,017 0.967 0.28 1.82 0.19
FVII:C, % 1,403 107.6 30 207 24.4
FVII antigen, IU/ml 1,082 100.1 36 190 26.0
FVIII antigen, IU/ml 1,940 0.9 0.3 7.1 0.3
FXIII activity, % 2,018 108.2 33 258 31.4
FXIIIA, U/ml 2,017 1.0 0 3.2 0.3
FXIIIB, U/ml 2,018 1.01 0.2 3.07 0.25
vWF, IU/ml 2,006 1.1 0.21 3.32 0.4
Fibrin lag time, s 2,484 81.00 2,555.0 347.0 8,996
Only those phenotypes found significant in the Stage 1 genome-wide association study are shown here (all results from Stage 1 are
given in the Supplementary Material).
BMI 5 body mass index; Fibrin lag time 5 lag phase of the turbidimetric clotting assay; FVII:C 5 factor VII clotting activity;
FXIIIA 5 FXIII A subunit; FXIIIB 5 FXIII B subunit; Max 5 maximum value; Min 5 minimum value; No. 5 sample size; SD
5 standard deviation; vWF 5 von Willebrand Factor.
TABLE 2. Stages 2 and 3: Characteristics of the Ischemic Stroke Collections
Cohort WTCCC2 MORGAMa MetaStroke
Cases Controls Cases Noncases Cases Controls
No. (% females) 3,548 (43.5) 5,972 (49.4) 715 (19.4) 2,932 (14.7) 8,884 55,254
Age, mean yr (SD) 70.5 (12.9) NA 60.4 (8.1) 59.1 (8.3) 67.1 (10.5) 59.4 (9.9)
BMI, mean kg/m2 (SD) NA NA 27.9 (4.5) 27.0 (4.1) NA NA
Age and BMI refer to values at the baseline of the follow-up.
aMOnica Risk, Genetics, Archiving and Monograph (MORGAM) is a population cohort with prospective follow-up for cases.
Genotyping for this study was performed in a case–cohort setting.
BMI 5 body mass index; NA 5 not available; No. 5 sample size; SD 5 standard deviation; WTCCC2 5 Wellcome Trust Case
Control Consortium 2.
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if they had call rates <80% or if reported gender was discord-
ant with gender-specific markers. We removed pairs of samples
showing concordance indicative of being duplicates. MetaStroke
genotyping results were imputed to HapMap2 using MACH2.
Where SNPs were imputed, r2 values were >0.9. Four SNPs
analyzed in these cohorts were meta-analyzed using a fixed
effects model with the metan module in Stata version 10.
Results
The characteristics of the 2,128 twin participants are
shown for TUK in Table 1 and Supplementary Table 1
(Stage 1). The mean age of the twins was 50.4 years, and
the sample included 87 (4.4%) males. All were of North
European descent. The sample size varied between assays;
for clarity, the number of subjects is included in the
tables for each phenotype.
Details of the clinical collections of stroke cases and
controls are shown in Table 2.
Stage 1
There were a number of strikingly strong genotype–phe-
notype associations identified in the TUK discovery
group, and in total 524 associations were found having p
< 5 3 1028. The 524 SNPs identified as significant ge-
nome-wide were mostly associated with coagulation fac-
tor phenotypes; there was 1 association with lag time to
TABLE 3. Stage 1: Independent SNPs (n 5 23) Found with p < 5 3 1028 in TwinsUK
Chr SNP Position Gene A1 A2 Freq A1 Trait Effect SE p
6 rs5985 6263794 F13A1 C A 0.741 FXIII activity 21.077 0.037 2.6 3 102186
6 rs3024321 6263125 F13A1 A G 0.679 FXIII activity 20.891 0.035 8.4 3 102142
9 rs505922 135139050 ABO T C 0.68 vWF 20.561 0.035 4.71 3 10257
9 rs643434 135132176 ABO G A 0.656 vWF 20.51 0.034 1.1 3 10249
13 rs10665 112800832 F7/F10 A G 0.878 FVII:C 0.847 0.059 2.37 3 10247
13 rs2181540 112801165 F7/F10 T C 0.876 FVII:C 0.834 0.058 1.18 3 10246
13 rs6041 112820708 F7/F10 G A 0.892 FVII:C 0.877 0.062 1.93 3 10245
1 rs10922162 195337399 CFHR4 C T 0.839 FXIIIA 0.521 0.045 1.55 3 10230
1 rs12116643 195239806 CFHR4 T C 0.84 FXIIIA 0.515 0.045 4.89 3 10230
9 rs651007 135143696 ABO C T 0.81 FVIII 20.461 0.044 1.94 3 10225
13 rs3211770 112841850 F7/F10 G A 0.879 FVII:C 0.534 0.059 2.98 3 10219
1 rs7410943 195421644 CFHR4 A G 0.531 FXIIIB 0.301 0.034 3.42 3 10219
1 rs4915559 195153393 CFHR4 T C 0.759 FXIIIA 0.339 0.038 7.3 3 10219
6 rs11243081 6282505 F13A1 C T 0.676 FXIIIA 20.299 0.035 5.13 3 10218
6 rs17142067 6286286 F13A1 A C 0.67 FXIIIA 20.299 0.035 1.24 3 10217
9 rs8176743 135121236 ABO C T 0.939 vWF 20.582 0.068 1.59 3 10217
6 rs1318606 6276935 F13A1 T C 0.569 FXIIIA 20.273 0.032 4.39 3 10217
13 rs555212 112804541 F7/F10 G A 0.768 FVII:C 20.367 0.046 1.07 3 10215
9 rs10982156 116127885 ORM1 T A 0.939 FX 0.456 0.072 2.47 3 10210
1 rs1410996 194963556 CFHR4 G A 0.585 FXIIIA 0.203 0.033 1.32 3 10209
5 rs12518614 6377293 FLJ33360 A G 0.954 vWF 20.463 0.077 1.52 3 10209
13 rs9533425 42668474 ENOX1 G C 0.801 Fibrin lag time 20.308 0.051 1.9 3 10209
1 rs2022309 94825064 F3 G T 0.701 D-dimer 20.244 0.045 4.32 3 10208
Of the 524 genome-wide significant associations identified in Stage 1, only independent SNPs are shown, and where associated
with multiple traits, the most significant result is given (all Stage 1 results are listed in Supplementary Table 2). The effect size
(Effect) and SE are expressed in terms of standard deviation for each phenotype. The probabilities for association (p) are from
multivariate models using single SNP genotypes as independent variables and age as covariate.
A1 5 allele 1; A2 5 allele 2; Chr 5 chromosome; Effect 5 beta of regression analysis; Fibrin lag time 5 lag phase of the turbidi-
metric clotting assay; Freq A1 5 frequency of allele 1; FVII:C 5 factor VII clotting activity; FXIIIA 5 FXIII A subunit; FXIIIB
5 FXIII B subunit; SE 5 standard error of beta; SNP 5 single nucleotide polymorphism; vWF 5 von Willebrand Factor.
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fibrin clot formation. After the interdependence of the
SNPs had been established by backward stepwise regres-
sion analysis, 23 statistically independent SNPs were
identified for examination in Stage 2 (shown in Table 3).
The strongest signals were observed for SNP rs5985 in
the F13A1 gene (encoding the FXIII A subunit) and
FXIII activity (p 5 2.6 3 102186), followed by
rs2731672 in the F12 gene associated with FXII concen-
tration (encoding FXII; p 5 1.3 3 102115; Supplemen-
tary Table 2) and rs505922 in the ABO gene with vWF
(p 5 4.7 3 10257; see Table 3) and factor VIII (p 5
1.2 3 10236; see Supplementary Table 2). Further coag-
ulation-related phenotype–SNP associations were identi-
fied for rs10665 in F7/MCF2L and FVII clotting activity
(p 5 2.4 3 10247), and rs2022309 in the F3 gene
(encoding tissue factor) with D-dimer concentration (p
5 4.3 3 1028).
A clear relationship was found between plasma
FXIII A subunit and SNP rs12137359 (p 5 1.0 3
10227) lying within the gene ZBTB41 (zinc finger and
BTB domain containing 41, a highly conserved gene).
However, this region on chromosome 1q is rich with
candidate genes, and the SNP in question lies down-
stream of the CFH and CFHR1-5 genes (encoding com-
plement factor H and CFH-related proteins 1 to 5) as
well as F13B (encoding FXIII B subunit). There is also
an association in this same region between rs800292 in
the CFH gene and FXIIIA concentration (p 5 1.5 3
10212).
Stage 2
In the MORGAM study, 6 of the 23 independent SNPs
were available for lookup. None of the SNPs was signifi-
cantly associated with ischemic stroke in this study group
or in WTCCC2, although there was a suggestion of an
effect for rs505922 in both MORGAM (T allele, beta 5
20.126, p 5 0.067) and WTCCC2 (T allele, beta 5
20.054, p 5 0.097). In the meta-analysis of WTCCC2
and MORGAM, SNP rs505922 in the ABO gene was
associated with ischemic stroke (beta for T allele 5
20.067, p 5 0.023), with the major T allele being pro-
tective against stroke (Table 4).
Stage 3
We examined the association of the 4 ABO SNPs in the
large Meta-Stroke dataset (Table 5, with genotyping
details in Supplementary Table 3) and further explored
their relationship with stroke subtype in Meta-Stroke and
WTCCC2. Results for ischemic stroke overall are shown
in Table 6 (positive results) and are illustrated by a forest
plot (Fig 2). The results show an association for lead
SNP rs505922 C allele with ischemic stroke (odds ratio
[OR] 5 1.07, 95% confidence interval [CI] 5 1.03–
1.11, p 5 0.0006). Two other ABO SNPs also showed
significant association: rs643434 (for A allele, meta-anal-
ysis logistic regression OR 5 1.06, 95% CI 5 1.02–
1.11, p 5 0.002) and rs651007 (C allele, OR 5 1.07,
95% CI 5 1.02–1.12, p 5 0.007; see Table 6). Analysis
by stroke subtype for SNP rs505922 showed association
with cardioembolic stroke (OR 5 1.13, 95% CI 5
1.11–1.15, p  0.001), and large-vessel stroke (OR 5
1.23, 95% CI 5 1.07–1.18, p 5 0.001), but there was
no association with small-vessel disease (p 5 0.811;
Table 7).
Finally, to determine whether the genetic influence
was acting through known risk factors, we performed
subgroup analysis in the sample having this information,
WTCCC2–Munich. Adjusting for hypertension,
TABLE 4. Stage 2: Meta-Analysis of the Independent SNPs in Stroke
SNP A1 A2 MORGAM WTCCC2 Meta-Analysis
Cases Noncasesa Cases Controls Effect SE OR 95% CI p
rs505922 C T 544 2,411 3,548 5,972 0.067 0.029 1.06 1.01 1.14 0.023
rs651007b T C 609 2,348 3,548 5,972 0.053 0.035 1.05 0.98 1.13 0.130
rs10665 A G 608 2,339 3,548 5,972 0.049 0.046 1.05 0.96 1.15 0.282
rs5985 A C 593 2,330 3,548 5,972 20.027 0.033 0.97 0.91 1.04 0.416
rs2022309 T G 561 2,167 3,548 5,972 0.014 0.031 1.01 0.95 1.08 0.648
rs1211664b T C 543 2,410 3,548 5,972 0.008 0.038 1.01 0.93 1.09 0.840
Of the 23 independent SNPs identified in Stage 1, 6 were available in both MORGAM and WTCCC2.
aNoncases of the random subcohort of the case–cohort set of MORGAM.
bFor WTCCC2, SNPs rs12116643 and rs651007 were imputed in all cases and controls.
A1 5 allele 1; A2 5 allele 2; CI 5 confidence interval; Effect 5 effect size (beta); OR 5 odds ratio; SE 5 standard error of
effect; SNP 5 single nucleotide polymorphism; WTCCC2 5 Wellcome Trust Case Control Consortium 2.
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hypercholesterolemia, diabetes, and smoking had a small
effect on the strength of the association (unadjusted: beta
5 0.159, 95% CI 5 0.023–0.294, p 5 0.022; adjusted:
beta 5 0.160, 95% CI 5 0.010–0.309, p 5 0.036).
Discussion
Ischemic stroke accounts for considerable morbidity and
mortality in Western countries, and treatment is limited
at present. Our 3-stage study design optimized power for
discovery of common genetic variants predisposing to is-
chemic stroke and stroke subtype. We performed a GWA
study of intermediate coagulation and fibrinolytic pheno-
types in healthy volunteers to examine the genetic deter-
minants of end-stage coagulation and went on to study
their influence on stroke and stroke subtype. We identi-
fied a large number of genetic variants associated with
measures of coagulation factors, both functional and anti-
genic, some of which have been included in GWA meta-
analyses of coagulation.23 We confirmed that polymor-
phisms in the ABO gene were significantly associated
with vWF and FVIII levels in healthy volunteers. Signifi-
cant associations between SNPs in ABO and levels of
vWF (rs505922, rs643434, rs8176743) and/or FVIII
(rs505922, rs651007) were identified; we went on to
demonstrate significant associations between ABO SNPs,
in particular rs505922, and ischemic stroke (see forest
plot in Fig 2).
The associations between FVIII levels and the ABO
gene variant rs505922, and between ABO and coronary
disease, suggest a possible mechanism behind the well-
documented association between the ABO blood group
and risk of vascular disorders. Non-O blood groups are
at increased risk of stroke,24 peripheral vascular disease,
and myocardial infarction (MI) but not coronary artery
disease (as assessed by angina, summarized by Wu et
al25), and this suggests that end-stage coagulation is the
critical determinant. The association we found with
FVIII levels may account for this. Recent GWA studies
of MI have identified variants within the ABO gene that
predispose to MI,26,27 and this relationship appears to
hold for common forms of thrombotic stroke; we found
evidence of association in large-vessel and cardioembolic
stroke, but there was no association with small-vessel dis-
ease. At present, none of the SNPs significantly associ-
ated with stroke is reported to be associated with known
risk factors such as hypertension, hyperlipidemia,
TABLE 5. Characteristics of the Stroke Collections in the MetaStroke Consortium (Stage 3)
Center Cases Controls/Noncases % Female
No. Age, Mean (SD) % Female No. Age, Mean (SD)
ARIC 385 57.3 (5.3) 39.7 8,803 54.1 (5.7) 53.6
ASGC 1,162 72.9 (13.2) 40.8 1,195 66.3 (7.5) 49.8
CEDIR 372 56.1 (15.8) 37.1 407 50.9 (8.2) 12.5
BRAINS 394 68.3 (14.7) 41 444 >65 64.2
CHS 454 81.6 (6.11) 55 2,817 85.8 (5.64) 55
DeCODE 2,401 77.2 (11.3) 46 27,082 50.8 (21.4) 62
FHS 171 80 (10) 55 4,164 NA NA
GASROS 516 66.7 (14.6) 39.7 1,202 47.5 (8.5) 40.9
GEOS 448 41.0 (7.0) 38.6 498 39.5 (6.7) 43.4
HPS 578 64.9 (7.5) 25 468 59.2 (9.3) 33
HVH 566 69.2 (8.64) 66.2 1,290 66.6 (9.13) 52.3
ISGS 1,070 66.6 (14.6) 43.3 1,488 64.1 (17.3) 51.9
Rotterdam 367 70.8 (7.5) 54.8 5,396 69.0 (9.0) 59.7
Totala 8,884 67.1 (10.5) 44.9 55,254 59.4 (9.9) 48.2
Details of all 13 cohorts contributing to the MetaStroke meta-analysis are shown.
aTotals were calculated for controls without FHS or BRAINS where precise data were unavailable.
ARIC 5 Atherosclerosis Risk in Communities; ASGC 5 Australian Stroke Genetics Collaborative; BRAINS 5 Bio-Repository of
DNA in Stroke; CHS 5 Cardiovascular Health Study; FHS 5 Framingham Heart Study; GASROS 5 Genes Affecting Stroke
Risk and Outcome Study; GEOS 5 Genetics of Early Onset Stroke Study; HPS 5 Heart Protection Study; HVH 5 Heart and
Vascular Health; ISGS 5 Ischemic Stroke Genetics Study; No. 5 sample size; SD 5 standard deviation.
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TABLE 6. Meta-Analysis of the ABO Locus in the MetaStroke Consortium: Stage 3
SNP Study Cases Controls/
Noncases
A1 A2 Freq A1 Beta SE p
rs651007 ARIC 385 8,803 C T 0.773 20.04 0.085 0.636
ASGC 1,177 1,195 C T 0.796 20.117 0.073 0.109
BRAINS 394 444 C T 0.803 0.033 0.123 0.786
CEDIR 372 407 C T 0.776 20.192 0.123 0.12
CHS 454 2,817 C T 0.788 20.109 0.106 0.302
DeCODE 2,393 26,982 C T 0.852 20.06 0.044 0.175
FHS 171 4,335 C T 0.79 0.065 0.149 0.664
GASROS 516 1,202 C T 0.686 20.065 0.082 0.429
HPS 578 468 C T 0.791 20.058 0.107 0.588
HVH 566 1,290 C T 0.776 20.028 0.119 0.814
ISGS 1,070 1,488 C T 0.8 20.158 0.076 0.037
Rotterdam 367 5,396 C T 0.794 0.038 0.094 0.168
Meta-analysis 8,443 54,827 C T 0.068 0.025 0.007
rs643434 ARIC 385 8,803 A G 0.368 0.186 0.073 0.011
ASGC 1,177 1,195 A G 0.34 0.149 0.062 0.017
BRAINS 394 444 A G 0.309 20.122 0.109 0.266
CEDIR 372 407 A G 0.378 0.099 0.104 0.34
CHS 454 2,817 A G 0.366 0.07 0.068 0.307
DeCODE 2,393 26,988 A G 0.283 0.043 0.033 0.195
FHS 171 4,335 A G 0.348 0.006 0.115 0.956
HPS 578 468 A G 0.345 0.054 0.094 0.567
HVH 566 1,290 A G 0.367 0.054 0.076 0.48
ISGS 1,070 1,488 A G 0.339 0.047 0.063 0.458
Rotterdam 367 5,396 A G 0.351 0.016 0.076 0.041
Meta-analysis 7,927 53,631 A G 0.062 0.02 0.002
rs505922 ARIC 385 8,803 C T 0.345 0.172 0.074 0.02
ASGC 1,177 1,195 C T 0.317 0.176 0.063 0.005
BRAINS 394 444 C T 0.308 20.108 0.108 0.318
CEDIR 372 407 C T 0.351 0.122 0.105 0.248
CHS 454 2,817 C T 0.342 0.059 0.068 0.391
DeCODE 2,393 26,965 C T 0.74 0.052 0.034 0.129
FHS 171 4,335 C T 0.325 0.04 0.115 0.727
GASROS 516 1,202 C T 0.3 0.094 0.081 0.249
HPS 578 468 C T 0.327 0.047 0.094 0.619
HVH 566 1,290 C T 0.344 0.054 0.077 0.484
ISGS 1,070 1,488 C T 0.329 0.039 0.061 0.528
Rotterdam 367 5,396 C T 0.666 0.005 0.077 0.005
Meta-analysis 8,443 54,810 C T 0.391 0.066 0.02 0.001
Meta-analysis of ischemic stroke performed in MetaStroke cohorts in the ABO locus (those 3 SNPs having positive results shown).
Results of the meta-analysis of the nonsignificant SNP rs8176743 are given in Supplementary Table 2.
A1 5 allele 1; A2 5 allele 2; ARIC 5 Atherosclerosis Risk in Communities; ASGC 5 Australian Stroke Genetics Collaborative;
Beta 5 effect size; BRAINS 5 Bio-Repository of DNA in Stroke; CHS 5 Cardiovascular Health Study; FHS 5 Framingham
Heart Study; Freq 5 frequency; GASROS 5 Genes Affecting Stroke Risk and Outcome Study; HPS 5 Heart Protection Study;
HVH 5 Heart and Vascular Health; ISGS 5 Ischemic Stroke Genetics Study; SE 5 standard error; SNP 5 single nucleotide
polymorphism.
TABLE 7. Meta-Analysis of Single Nucleotide Polymorphism rs505922 in the ABO Locus by Stroke Subtype
(Stage 3)
Center Cases Controls/
Noncases
A1 A2 Freq A1 Beta SE p
Cardioembolic
ARIC 93 9,095 C T 0.345 0.403 0.148 0.006
ASGC 240 1,195 C T 0.305 0.252 0.106 0.017
BRAINS 40 444 C T 0.308 20.032 0.254 0.900
CEDIR 65 407 C T 0.351 0.303 0.196 0.123
CHS 147 2,817 C T 0.342 0.182 0.118 0.125
DECODE 399 26,965 C T 0.260 0.004 0.081 0.960
FHS 48 4,335 C T 0.325 0.067 0.241 0.781
GASROS 169 1,202 C T 0.300 0.171 0.124 0.169
HVH 88 1,290 C T 0.342 0.108 0.161 0.502
ISGS 247 2,311 C T 0.329 0.077 0.101 0.444
WTCCC-G 330 797 C T 0.373 0.120 0.095 0.208
WTCCC-UK 460 5,175 C T 0.325 0.068 0.073 0.350
Meta-analysis 2,326 56,033 C T 0.325 0.122 0.010 0.0002
Large artery
ARIC 31 9,157 C T 0.345 0.490 0.255 0.055
ASGC 421 1,195 C T 0.306 0.163 0.087 0.060
BRAINS 118 444 C T 0.308 20.075 0.161 0.639
CEDIR 74 407 C T 0.351 0.235 0.185 0.205
DECODE 240 26,965 C T 0.260 0.025 0.105 0.815
GASROS 95 1,202 C T 0.300 20.076 0.169 0.653
HVH 61 1,290 C T 0.342 0.127 0.176 0.470
ISGS 229 2,329 C T 0.329 0.165 0.103 0.112
WTCCC-G 346 797 C T 0.373 0.213 0.096 0.026
WTCCC-UK 498 5,175 C T 0.325 0.075 0.07 0.281
Meta-analysis 2,113 48,961 t c 0.324 0.116 0.026 0.001
Small vessel
ARIC 63 9,125 C T 0.345 20.185 0.193 0.339
ASGC 310 1,195 C T 0.305 0.197 0.098 0.043
BRAINS 113 444 C T 0.308 20.045 0.168 0.787
CEDIR 25 407 C T 0.351 0.007 0.312 0.981
CHS 73 2,817 C T 0.339 20.110 0.176 0.533
DECODE 255 26,965 C T 0.260 20.035 0.101 0.728
GASROS 38 1,202 C T 0.300 0.320 0.244 0.190
HVH 173 1,290 C T 0.342 0.054 0.125 0.663
ISGS 201 2,357 C T 0.329 20.206 0.115 0.071
WTCCC-G 106 797 C T 0.373 0.267 0.153 0.082
WTCCC-UK 474 5,175 C T 0.325 20.096 0.073 0.192
Meta-analysis 1,831 51,774 C T 0.325 20.009 0.038 0.811
Subtypes of ischemic stroke were examined in MetaStroke, WTCCC-G, and WTCCC-UK. Subtyping included cardioembolic,
large-artery, and small-vessel disease.
A1 5 major allele; A2 5 minor allele; ARIC 5 Atherosclerosis Risk in Communities; ASGC 5 Australian Stroke Genetics Col-
laborative; Beta 5 effect size; BRAINS 5 Bio-Repository of DNA in Stroke; CHS 5 Cardiovascular Health Study; FHS 5 Fra-
mingham Heart Study; Freq 5 frequency; GASROS 5 Genes Affecting Stroke Risk and Outcome Study; HVH 5 Heart and
Vascular Health; ISGS 5 Ischemic Stroke Genetics Study; p 5 probability of association; SE 5 standard error of the effect;
WTCCC-G 5 Wellcome Trust Case Control Consortium, German subcohort; WTCCC-UK 5 WTCCC, UK subcohort.
diabetes, or propensity to drink alcohol or smoke. Sub-
group analysis of the study group having risk factor in-
formation (WTCCC2–Munich) attenuated the strength
of the association but did not suggest that the action of
the genetic variation was predominantly though 1 of
these risk factors.
SNP rs505922 represents a single base pair change
from T to C at position 135,139,050 and lies within the
first intron of the ABO gene, although its haplotype
block contains the promoter and introns 1 and 2. The
minor allele frequency of this SNP is 36% in Northern
Europeans. The ABO gene encodes a glycosyltransferase
enzyme that catalyses the transfer of different carbohy-
drate groups onto the H antigen, thus forming A and B
antigens of the ABO system. In support of a functional
role in thrombosis (as opposed to atherosclerosis), the
non-O blood group has also been shown to be a risk fac-
tor for venous thrombosis,28 and in a large prospective
study, pulmonary embolism.29 A previous GWA study
identified the same SNP, rs505922, to be associated with
venous thromboembolism,30 and a recent GWA study of
blood metabolites suggests that this locus may act via an
effect on fibrinogen phosphorylation.31
Our results demonstrate that the association
between ABO SNPs and ischemic stroke is limited to
large-artery and cardioembolic stroke, but absent in
small-vessel stroke. Thromboembolism plays an impor-
tant role in pathogenesis of both cardioembolic and
large-artery stroke, with thrombus arising in the heart
and on larger-artery atherosclerotic plaques, respectively,
which may break off and embolize into the cerebral cir-
culation. In both stroke subtypes, cerebral emboli can be
detected in the cerebral circulation using transcranial
Doppler,32 and antithromboembolic therapy reduces
stroke risk. Recently, vWF inhibition has been shown to
reduce cerebral thromboembolism in man,33 a clinical
observation that is in keeping with our findings. In con-
trast, the pathogenesis of small-artery stroke is unclear,
and the role of thrombosis remains uncertain.34 Our
results suggest that thrombosis may be less important for
this stroke subtype and explain why antithromboembolic
medication is less effective. The subtype specificity we
have identified is consistent with others’ results; of 5
GWA studies identified and replicated, 2 have been stud-
ies of cardioembolic stroke,35,36 2 of large-vessel stroke,37
and 1 of small-vessel stroke.38 Taken together, these data
highlight that the clinical endpoint of ischemic stroke
represents a varied phenotype likely resulting from multi-
ple pathogenic mechanisms.
Other associations between SNPs and intermediate
phenotypes included rs12137359 and FXIII activity and
rs800292 and FXIIIA subunit levels. Both variants are
FIGURE 2: Forest plot shows results of the meta-analysis of rs505922 in Meta-Stroke. An inverse variance fixed effects model
was used. The central filled dots represent odds ratios (ORs) in the individual cohorts, with their 95% confidence intervals (CIs;
dark lines), and gray squares are proportional to sample size. The hollow diamond represents the meta-effect observed overall
(p 5 0.0006). ARIC 5 Atherosclerosis Risk in Communities; ASGC 5 Australian Stroke Genetics Collaborative; BRAINS 5 Bio-
Repository of DNA in Stroke; CHS 5 Cardiovascular Health Study; FHS 5 Framingham Heart Study; GASROS 5 Genes Affect-
ing Stroke Risk and Outcome Study; HPS 5 Heart Protection Study; HVH 5 Heart and Vascular Health; ISGS 5 Ischemic Stroke
Genetics Study.
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found close to the gene encoding the FXIIIB subunit,
which acts as a carrier protein for FXIIIA in the circula-
tion and stabilizes FXIIIA to regulate activation; how-
ever, these SNPs were not associated with MI or ische-
mic stroke. We also identified associations between
SNPs in the vicinity of the F7 gene and FVII:C, con-
sistent with a number of studies that have previously
identified relationships between variation in the struc-
tural genes for FVII and circulating levels.39,40 No other
SNPs significantly associated with coagulation interme-
diate phenotypes were significantly associated with is-
chemic stroke.
There are a number of limitations to this work.
First, TUK is predominantly female in its composition,
for historical reasons. Although TUK subjects are repre-
sentative of the general population variation8 and there is
no evidence of an effect of gender on the ABO predispo-
sition to cardiovascular disease, the associations identified
in Stage 1 are pertinent to females from Northern
Europe. Second, the clinical studies used for Stage 2
were heterogeneous in many respects. We decided that it
was of overriding importance to obtain a large sample, so
we combined prospective and cross-sectional studies.
One of the main strengths of the study design was the
use of multiple novel intermediate phenotypes, as well as
having the power to investigate stroke subtypes. The
Stage 3 study groups had differing methods of genotyp-
ing and imputation, but methods have been shown to be
broadly comparable.41
In conclusion, using end-stage coagulation interme-
diate traits in healthy volunteers, we identified 23 ge-
nome-wide independent coagulation-associated SNPs,
which were investigated in a number of clinical collec-
tions of stroke. Genetic variant rs505922 in the ABO
locus was found to be associated with ischemic stroke,
and in particular the subtypes large-vessel and cardioem-
bolic stroke, but not small-vessel disease. This SNP was
highly associated with vWF and FVIII in the discovery
phase, and this observation throws light on possible
mechanisms underlying end-stage coagulation in cardio-
vascular disease. It seems that common genetic variants
exert some of their influence on end-stage stroke through
coagulation, and further work is needed to tease apart
these complex networks of interactions. The identifica-
tion of the ABO locus through its association with vWF
and FVIII points the way for mechanistic work to under-
stand better the role of these 2 coagulation factors in
end-stage arterial thrombosis.
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